Physician profile
Parth Rali
NPI 1326398421
$313,803.73
in general payments reported to CMS, 2019-2025
24 companies · $82K in 2025
The $82K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $100 · 2021: $118 · 2022: $88K · 2023: $34K · 2024: $110K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Consulting Fee: $64K · Travel and Lodging: $38K · Food and Beverage: $4,366 · Education: $2,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,043.50 |
| Consulting Fee | $64,182.50 |
| Travel and Lodging | $38,300.31 |
| Food and Beverage | $4,366.16 |
| Education | $2,324.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $170,536.96 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Stryker Corporation | $39,510.80 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $35,353.66 | 2022-2024 | Xarelto |
| Viz.Ai, INC. | $14,040.83 | 2022 | |
| Merck Sharp & Dohme LLC | $13,169.23 | 2023-2025 | Winrevair |
| United Therapeutics Corporation | $9,913.04 | 2020-2025 | Tyvaso, Remodulin, Remodulin |
| Actelion Pharmaceuticals US, INC. | $8,833.10 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Penumbra, INC. | $7,275.77 | 2023-2025 | Indigo System |
| Cardinal Health 200 LLC | $6,787.93 | 2023-2024 | |
| Aidoc Medical LTD | $4,750.00 | 2025 | Briefcase |
| Nabriva Therapeutics, Plc | $2,057.77 | 2022 | |
| Pfizer INC. | $700.00 | 2022 | |
| Angiodynamics, INC. | $321.54 | 2025 | Alphavac |
| Abiomed | $169.76 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $131.88 | 2021-2025 | Breztri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $119.34 | 2019-2023 | Xolair |
| Insmed, INC. | $56.52 | 2022-2024 | Arikayce |
| Harmony Biosciences LLC | $27.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.27 | 2019 | |
| Sandoz INC. | $16.74 | 2025 | Treprostinil |
| Glaxosmithkline, LLC. | $11.98 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Rali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.